Teva (TEVA), Par Pharma (PRX) said to lose bid to sell the generic form of Glaxo's (GSK) Lovaza
Tweet Send to a FriendGet Alerts TEVA Hot Sheet
Price: $38.95 -1.02%
Overall Analyst Rating:
NEUTRAL (
Up)
Dividend Yield: 3.2%
EPS Growth %: -23.8%
Overall Analyst Rating:
NEUTRAL (
Up)Dividend Yield: 3.2%
EPS Growth %: -23.8%
Trade TEVA Now!
Teva Pharmaceutical (Nasdaq: TEVA), Par Pharma (NYSE: PRX) said to lose bid to sell the generic form of Glaxo's (NYSE: GSK) Lovaza.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- From Novel Research to Innovative Medicines: GlaxoSmithKline Launches Discovery Fast Track Competition for Academic Researchers
- Merck's (MRK) Suvorexant Helps People Sleep, Says FDA
- Oncolytics Biotech (ONCY) REOLYSIN w/ REO 020 Met Primary Endpoint in Phase 2
Create E-mail Alert Related Categories
FDA, General News
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
